Autologous T cell therapy against CD19: Additional Phase I/II data

Data from 7 patients with refractory aggressive diffuse large B cell lymphoma (DLBCL) in the Phase I portion of the open-label, U.S. Phase I/II ZUMA-1 trial showed that a single infusion of IV KTE-C19...